10-Q: BullFrog AI Faces Nasdaq Delisting Risk Amidst Liquidity Concerns

BullFrog AI Holdings, Inc. reported a significant decrease in cash and equity, triggering a Nasdaq non-compliance notice, despite recognizing its first collaboration revenue.

Summary

• Net loss for the nine months ended September 30, 2025, was $5,017,894, a slight improvement from $5,278,904 in the prior year.
• Recognized first collaboration revenue of $116,670 for the nine months ended September 30, 2025, from Eleison Pharmaceuticals Inc.
• Cash and cash equivalents decreased significantly to $1,990,712 as of September 30, 2025, from $5,435,983 at December 31, 2024.
• Total stockholders' equity declined to $1,943,655, falling below Nasdaq's minimum $2,500,000 requirement.
• Received a Nasdaq non-compliance letter on August 21, 2025, and was granted an extension until February 17, 2026, to regain compliance.
• Entered into an At-The-Market (ATM) sales agreement with BTIG, LLC, raising $1.1 million net proceeds through September 30, 2025, with approximately $2.0 million additional capacity under current public float limitations.
• Signed a purchase agreement with Lincoln Park Capital Fund, LLC for up to $10.0 million in common stock over 36 months, issuing 147,682 shares ($207,000) as a commitment fee.
• Material weaknesses in internal controls over financial reporting remain unremediated as of September 30, 2025.

Sentiment

Score: 3

Explanation: The company faces severe liquidity issues and a Nasdaq delisting threat, indicating significant financial distress. While there's initial revenue and new collaborations, these are overshadowed by the going concern warning and unremediated internal control weaknesses. The capital raise efforts are ongoing but insufficient to fully address immediate needs.

Positives

• Recognized first collaboration revenue of $116,670 for the nine months ended September 30, 2025, compared to zero in the prior year.
• Net loss for the nine months ended September 30, 2025, slightly improved to $5,017,894 from $5,278,904 in the same period of 2024.
• Entered into a strategic collaboration with Sygnature Discovery for joint marketing of the BullFrog Data Networks platform.
• Secured new financing avenues through an ATM agreement and a purchase agreement with Lincoln Park Capital Fund, LLC, providing potential capital of up to $20 million and $10 million respectively (subject to limitations and conditions).
• Research and development expenses decreased by $229,860 for the nine months ended September 30, 2025, compared to the same period in 2024.
• General and administrative expenses decreased by $119,894 for the nine months ended September 30, 2025, compared to the same period in 2024.

Negatives

• Cash and cash equivalents decreased significantly to $1,990,712 as of September 30, 2025, from $5,435,983 at December 31, 2024.
• Total stockholders' equity decreased to $1,943,655 as of September 30, 2025, from $4,963,740 at December 31, 2024.
• The company is not in compliance with Nasdaq's minimum stockholders' equity requirement of $2,500,000.
• The current cash position is not sufficient to fund planned operations for at least a year, raising substantial doubt about the company's ability to continue as a going concern.
• Material weaknesses in internal controls over financial reporting remain unremediated.
• Net cash provided by financing activities decreased significantly to $996,999 for the nine months ended September 30, 2025, from $5,952,472 in the prior year.
• Interest income decreased to $83,089 for the nine months ended September 30, 2025, from $204,868 in the prior year, primarily due to a lower average cash balance.

Risks

• Going Concern: The company has generated negative cash flows from operations and operated at a net loss since inception, and its cash balance is not sufficient to fund planned operations for at least a year, raising substantial doubt about its ability to continue as a going concern.
• Nasdaq Delisting: The company is not in compliance with Nasdaq Listing Rule 5550(b)(1) requiring minimum stockholders' equity of $2,500,000 and faces potential delisting if it cannot regain compliance by February 17, 2026.
• Capital Requirements & Dilution: The company requires additional capital to execute its strategy, and there is no assurance that funding sources will provide sufficient capital or be on acceptable terms. Issuance of additional equity securities may be significantly dilutive to current shareholders.
• Reliance on Financing: The ability to continue operations is dependent on obtaining necessary financing or revenues, with no commitments for future funding other than the ATM Agreement and Lincoln Park facility.
• Internal Control Weaknesses: Material weaknesses in internal controls over financial reporting remain unremediated, posing a reasonable possibility that a material misstatement of financial statements would not be prevented or detected timely.
• Product Development & Commercialization: Future financial performance depends on successful development and commercialization of products and services, attracting and retaining customers, and expanding into new markets.
• Market Acceptance: Market acceptance and demand for products and services, pricing, and the changing regulatory environment are significant risks.
• Key Personnel: The ability to attract, retain, and motivate key personnel is crucial for business execution.

Future Outlook

The company anticipates securing additional capital through licensing agreements, collaborative arrangements, and the sale of equity securities or debt transactions. Management believes funding sources like the ATM Agreement and Lincoln Park equity line will be available, but there is no assurance of sufficient capital or acceptable terms. Failure to raise funds could lead to delays, scaling back, or elimination of research and product development programs. The company intends to continue evolving and improving its bfLEAP platform and plans to acquire rights to drugs at various development stages for in-house development and monetization within approximately 30 months.

Management Comments

• "Management believes that such funding sources will be available, including pursuant to the Company's at-the-market common stock sales facility provided by our ATM Agreement and pursuant to the Company's equity line of credit facility provided by our purchase agreement with Lincoln Park Capital Fund, LLC."
• "Management has concluded that the unaudited condensed consolidated financial statements in this filing on Form 10-Q fairly present, in all material respects, our financial position, results of operations and cash flows as of and for the periods presented in conformity with GAAP."
• "Management is in the process of implementing improvements to its internal controls over financial reporting."

Industry Context

BullFrog AI operates in the highly competitive and capital-intensive biopharmaceutical industry, leveraging AI/ML to address the high failure rates and costs of drug development. Its focus on precision medicine and de-risking development stages aligns with a growing trend in the industry to use advanced analytics for more efficient drug discovery. Collaborations with institutions like JHU-APL and LIBD, and partnerships with companies like Eleison and Sygnature, demonstrate a strategy to integrate into the broader drug development ecosystem, both through direct service and internal asset development. The industry is increasingly adopting AI/ML to synthesize complex, high-dimensional data, a challenge BullFrog AI aims to overcome with its bfLEAP platform.

Comparison to Industry Standards

• The company's strategy to use AI/ML for drug asset enablement and rescue late-stage failed drugs is a recognized approach in the biotech industry to mitigate high R&D costs and failure rates.
• The collaboration with Eleison Pharmaceuticals, a Phase III oncology company, for clinical trial optimization aligns with industry efforts to enhance trial efficiency and strategic planning using data insights.
• The partnership with Sygnature Discovery, a UK-based contract research organization, for introducing BullFrog Data Networks to its global client base, indicates a move towards broader market penetration, similar to other AI-driven platforms seeking to integrate with established CROs.
• The licensing agreements with Johns Hopkins University and George Washington University for specific drug candidates (e.g., Mebendazole for glioblastoma, siRNA for hepatocellular carcinoma) are standard practices for early-stage biotech companies building a pipeline from academic research.
• The data use agreement with the Lieber Institute for Brain Development (LIBD) for analyzing proprietary brain-related datasets for drug discovery is a strategic move to access unique data, a common competitive advantage sought by AI-driven drug discovery firms.
• The company's financial position, particularly the "going concern" warning and Nasdaq non-compliance, indicates significant challenges compared to more established or well-funded industry peers. Many early-stage biotechs face capital constraints, but the Nasdaq delisting risk highlights a more acute financial vulnerability.

Corporate Governance

Related Party Transactions

• Issuance of 147,682 shares of common stock valued at approximately $207,000 to Lincoln Park Capital Fund, LLC as a commitment fee for a purchase agreement.
• Vininder Singh, CEO and Director, had a 10b5-1 sales plan which expired on August 31, 2025, under which 50,000 shares were sold in Q3 2025.

Stakeholder Impact

• Shareholders: Significant dilution risk from ongoing and future equity raises (ATM, Lincoln Park). Potential for further share price decline due to Nasdaq delisting risk and going concern warning. Existing shares have seen significant dilution from past offerings.
• Employees/Management: Ongoing internal control remediation efforts may impact workload. Equity incentive plan amendment could benefit employees/management through future awards.
• Customers/Partners: New collaborations (Eleison, Sygnature, LIBD) indicate continued business development and potential for future revenue, but the company's financial instability could pose risks to long-term partnerships.
• Creditors: The going concern warning and liquidity issues increase risk for any current or future creditors.
• Regulatory Bodies (Nasdaq, SEC): Company is actively working to address Nasdaq compliance issues and internal control weaknesses, which are under regulatory scrutiny.

Next Steps

• Regain compliance with Nasdaq's minimum stockholders' equity requirement by February 17, 2026.
• Secure additional capital through licensing agreements, collaborative arrangements, equity sales, or debt transactions to fund operations for at least a year.
• Continue implementing improvements to internal controls over financial reporting, including transitioning accounting processes to an external firm, completing transfer to an enterprise accounting platform, reviewing control design and effectiveness, and ongoing monitoring.
• Continue to evolve and improve the bfLEAP AI/ML platform.
• Pursue new intellectual property development.
• Target large public health data sources and seek access to proprietary health data sources.
• Acquire rights to drugs at various stages of development for in-house development and monetization.
• Conduct late-stage clinical trials for drug rescue, requiring partners, drug supply, and regulatory services.
• Obtain finished drug product manufactured under good manufacturing practices for clinical use or sale.
• Await SEC effectiveness of the registration statement covering resale of shares to Lincoln Park Capital Fund, LLC to enable sales under the purchase agreement.

Key Dates

Recommendation

The company faces critical financial challenges, including a severe liquidity crisis with cash insufficient for a year of operations, leading to a "going concern" warning. It is also non-compliant with Nasdaq's minimum equity requirement and faces potential delisting. While there's initial revenue and new capital raise facilities, the amounts are limited or subject to conditions, and past financing has been highly dilutive. Unremediated material weaknesses in internal controls add further risk. These factors collectively indicate a high probability of significant downside risk and make the stock a strong sell for seasoned investors.

Keywords

AI/ML drug discovery, biopharmaceutical, precision medicine, bfLEAP platform, Nasdaq compliance, going concern, capital raise, biotech, pharmaceuticals, artificial intelligence, machine learning, drug development, SEC filing, 10-Q